



## AMENDMENTS TO THE CLAIMS

1. (Currently amended) A fused bicyclic pyrimidine derivative represented by the following general compound of formula (1), or a salt thereof:




wherein the rings A and B are each a benzene ring, which may have 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring selected from the group consisting of



each independently selected from the group consisting of a halogen atom, a C<sub>1</sub> to C<sub>6</sub> alkyl group, which may be substituted with a halogen atom, and a C<sub>1</sub> to C<sub>6</sub> alkoxy group;


the ring C is a 5- to 7-membered nitrogen-containing ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen atom, a sulfur atom, and an oxygen atom;

the ring C may further contain a substituent (a substituent selected from the group consisting of a C<sub>1</sub> to C<sub>6</sub> alkyl group, a hydroxyl group, a C<sub>1</sub> to C<sub>6</sub> alkoxy group, a formyl group, a C<sub>1</sub> to C<sub>6</sub> alkylcarbonyl group, a C<sub>1</sub> to C<sub>6</sub> alkoxy carbonyl group, a carbamoyl group, a mono- or di-substituted C<sub>1</sub> to C<sub>6</sub> alkylcarbamoyl group, a C<sub>1</sub> to C<sub>6</sub> alkylsulfonyl group, an amino group, a mono- or di-substituted C<sub>1</sub> to C<sub>6</sub> alkylamino group, a C<sub>1</sub> to C<sub>6</sub> alkylcarbonylamino group, a C<sub>1</sub> to C<sub>6</sub> alkoxy carbonylamino group, a C<sub>1</sub> to C<sub>6</sub> alkylsulfonylamino group, an oxo group, a 6-membered aromatic heterocyclic group, and a substituent represented by the following formula:





C<sub>6</sub> alkoxycarbonylamino group, a C<sub>1</sub> to C<sub>6</sub> alkylsulfonylamino group, an oxo group, a 6-membered aromatic heterocyclic group, and a substituent represented by the following formula:




wherein the ring D is a 3- to 7-membered nonaromatic heterocyclic ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen atom, a sulfur atom, and an oxygen atom and may further contain 1 or 2 oxo-substituted carbon atoms);


R is a hydrogen atom, a C<sub>1</sub> to C<sub>6</sub> alkyl group, a C<sub>1</sub>to C<sub>6</sub> alkylcarbonyl group, or a C<sub>1</sub>to C<sub>6</sub> alkylsulfonyl group; and

n is 2 or 3.

3. (Currently amended) The ~~fused bicyclic pyrimidine derivative~~compound according to claim 2, or a salt thereof, wherein in the ~~general~~ formula (1a), the ring C is represented by the following formula:




wherein R<sup>1</sup> is a hydroxyl group, a C<sub>1</sub>to C<sub>6</sub> alkoxy group, a formyl group, a C<sub>1</sub>to C<sub>6</sub> alkylcarbonyl group, a C<sub>1</sub>to C<sub>6</sub> alkoxycarbonyl group, a carbamoyl group, a mono- or di-substituted C<sub>1</sub>to C<sub>6</sub> alkylcarbamoyl group, an amino group, a mono- or di-substituted C<sub>1</sub>to C<sub>6</sub> alkylamino group, a C<sub>1</sub>to C<sub>6</sub> alkylcarbonylamino group, a C<sub>1</sub>to C<sub>6</sub> alkoxycarbonylamino group, a C<sub>1</sub>to C<sub>6</sub> alkylsulfonylamino group, an oxo group, a 6-membered aromatic heterocyclic group, or a substituent represented by the following formula:




wherein the ring D is a 3- to 7-membered nonaromatic heterocyclic ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen atom, a sulfur atom, and an oxygen atom and may further contain 1 or 2 oxo-substituted carbon atoms.

4. (Currently amended) The ~~fused bicyclic pyrimidine derivative~~compound according to claim 2, or a salt thereof, wherein in the ~~general~~ formula (1a), the ring C is represented by the following formula:




wherein X is  $\text{-O-}$  or  $\text{-S(O)}_q\text{-}$ ; and q is 0, 1, or 2.

5. (Currently amended) The ~~fused bicyclic pyrimidine derivative~~compound according to claim 2, or a salt thereof, wherein in the ~~general~~ formula (1a), the ring C is a group represented by the following formula:




wherein  $\text{R}^2$  is a hydrogen atom, a  $\text{C}_1$  to  $\text{C}_6$  alkyl group, a formyl group, a  $\text{C}_1$  to  $\text{C}_6$  alkylcarbonyl group, a  $\text{C}_1$  to  $\text{C}_6$  alkoxy carbonyl group, a carbamoyl group, a mono- or di-substituted  $\text{C}_1$  to  $\text{C}_6$  alkylcarbamoyl group or a  $\text{C}_1$  to  $\text{C}_6$  alkylsulfonyl group; and r is 1 or 2.

6. (Currently amended) The ~~fused bicyclic pyrimidine derivative~~compound according to claim 2, or a salt thereof, wherein in the ~~general~~ formula (1a), the ring C is represented by the following formula:



wherein  $\text{R}^{2'}$  is an acetyl group or a methylsulfonyl group; and r is 1 or 2.

7. (Currently amended) The ~~fused bicyclic pyrimidine derivative~~compound according to claim 2, or a salt thereof, wherein in the ~~general~~ formula (1a), the ring C is represented by the following formula:



8. (Currently amended) The ~~fused bicyclic pyrimidine derivative~~compound according to claim 7, or a salt thereof, wherein in the ~~general~~ formula (1a), n is 3.

9. (Currently amended) The ~~fused bicyclic pyrimidine derivative~~compound according to claim 7, or a salt thereof, wherein in the ~~general~~ formula (1a), R is a hydrogen atom, and n is 3.

10-11. (Cancelled)

12. (Currently amended) A method of ~~preventing or treating dysuria, including defective bladder functions such as increased urinary frequency and incontinence of urine,~~ in a patient in need thereof, which comprises administering to the patient a therapeutically effective amount of a ~~fused bicyclic pyrimidine derivative~~compound according to claim 1, or a salt thereof.

13-15. (Cancelled)

16. (Currently amended) A pharmaceutical composition comprising a ~~fused bicyclic pyrimidine derivative~~an effective amount of a compound of formula (I) according to claim 1, or a salt thereof, and a pharmaceutically acceptable adjuvant.

17. (New) The method according to claim 12, wherein the dysuria is increased urinary frequency or incontinence of urine.